INTRODUCTION
Fabry disease (MIM 301500) is a rare X-linked lysosomal storage disorder resulting from deficiency of alpha galactosidase A (GLA) and accumulation of its substrate globotriaosylceramide (Gb3) [1] . Clinical features include pain in the extremities (acroparesthesia), sweating abnormalities, a rash (angiokeratoma) and gastrointestinal symptoms. Progression to proteinuric renal failure, cardiac hypertrophy and stroke may occur [2] . The presentation is very heterogeneous, affecting both males and females of all ages. Broadly, two phenotypes have been recognized: an early onset classical form manifesting in childhood and a later onset form which often affects a single organ without the peripheral manifestations. However, the relationship of individual mutations to clinical presentation is not always clear, and the impact of other factors on progression is unknown. Treatment is by intravenous infusion of the missing enzyme [enzyme replacement therapy (ERT)], and while originally described in terms of effects on surrogates such as substrate clearance on biopsy [3, 4] , it has now been available for over 15 years, and the long-term clinical effects are emerging and new modalities of therapy are being described.
PATHOPHYSIOLOGY
Over 600 mutations encompassing the seven exons of the GLA gene have been described, with varying effects on aGal enzyme activity depending on type and site of mutation [5 substrate accumulation is qualitatively clear, the role of individual mutations in generation of quantitatively different levels of substrate and its derivatives in tissues and their impact on organ changes is not well understood. The accumulated sphingolipid substrate Gb3 is converted to lyso-Gb3 by acid ceramidase within tissues and is detectable on biopsy of affected organs, in the circulation and in the urine [7,8 && ] . Findings in an in-vitro model of increased collagen production after addition of lysoGb3 point to a critical role in the genesis of fibrosis found in heart and kidney, possibly through notch1 signalling [9 && ]. However, little lyso-Gb3 is found in the plasma of patients with some so-called late onset mutations associated with relatively preserved enzyme activity despite significant single organ effects such as left ventricular hypertrophy (LVH), posterior wall fibrosis, conduction defects and ensuing morbidity [10] .
DIAGNOSIS
Diagnosis in males is by confirmation of reduced aGal enzyme activity with confirmatory genotyping [11] . However, in females random X-inactivation in the peripheral blood may result in noninformative enzyme activity in the normal range and a requirement for genotyping of the GLA gene to confirm the diagnosis. Measurement of Gb3 substrate and its derivatives such as lyso-Gb3 within organs, plasma and urine may be helpful in classification and assignment of pathogenicity but is not independently discriminatory for diagnosis, because elevated levels have been found in patients with cardiac symptoms but without Fabry disease, suggesting a possible contributory role to other conditions [12 & ]. Screening studies of patients with relatively nonspecific symptoms may result in the detection of variants of unknown significance for which the pathogenic impact is unclear [13] . Recent consensus initiatives have attempted to define criteria for the diagnosis of Fabry disease when the pathogenicity of a new mutation has not previously been described. Critical attributes include demonstration of low enzyme activity, relevant clinical features and ultimately demonstration of substrate accumulation in the relevant organ by biopsy where possible [14] . Although classical and later onset forms of the condition often segregate with specific genotypes, this is not absolute, and each case should be individually assessed. For example, while the N215S GLA mutation has been denoted as a 'cardiac variant' presenting with cardiomyopathy, some patients have been described with proteinuria and renal failure [15] .
Prior to diagnostic testing, patients require genetic counselling and information in regard to possible future prognosis, therapy and implications of the condition for family making, employment and insurance. Pedigree analysis of an X-linked condition will be informative of genetically at risk individuals, and individuals may require support in communicating the possibility of a life-limiting diagnosis to other family members [16] . However, genetic screening of younger family members provides an opportunity for early diagnosis, assessment and therapy of individuals who might have otherwise only come to medical attention after a detrimental event.
SCREENING AND PREVALENCE
In early studies, the prevalence of Fabry disease was reported to be one in 117 000 (Australia) [17] , one in 468 000 (Netherlands) [18] and one in 833 000 (Portugal) [19] ; however, newborn screening has detected a higher incidence of GLA mutations, for example, one in 3100 newborn Italian males [20] and one in 1600 in Taiwan [21] . The pathogenicity and natural history of all mutations found in newborns is unknown, and there remain some ethical implications of such strategies. Screening in Taiwan has uncovered a large population of patients with a single GLA mutation resulting in a later onset cardiac predominant phenotype of Fabry disease with more immediate clinical relevance to parents and grandparents than the newborn index case [22] . The screening of targeted high-risk populations has informed prevalence in symptomatically enriched populations; a systematic review by Linthorst et al.
KEY POINTS
Fabry disease is a rare X-linked disorder resulting in renal dysfunction, left ventricular hypertrophy and stroke.
An early onset classical form is characterized by acroparesthesia, angiokeratoma, sweating abnormalities and corneal whorls; a later onset form with single organ, usually cardiac, manifestations is recognized.
The pathology of cardiac and renal dysfunction appears to involve fibrosis, and having occurred, this appears to limit the effects of Fabry-specific ERT.
New imaging biomarkers such as T1 mapping may allow the detection of early stages of the disease.
Long-term data on patients treated with ERT are now becoming available and point to better responses when patients are treated at an earlier stage. [23] of screening studies in high-risk groups showed a prevalence of 0.33% in male dialysis patients, 0.1% in female dialysis patients and at least 1% for patients with LVH. However, the prevalence in such screening studies may be artificially inflated as a result of removal of patients with other diagnoses and possible misattribution of pathogenicity to polymorphisms.
CLINICAL FEATURES AND CLASSIFICATION
In the classical early onset form of the condition, males with low enzyme activity present during childhood with pain, gastrointestinal symptoms and sweating abnormalities [24] . Intolerance to heat and exertion provokes painful episodes in the extremities and leads to a failure to participate in sporting activities, and pain crises at the time of febrile illnesses may prolong absence from school. Corneal opacities (cornea verticillata) and rash (angiokeratoma) in characteristic regions around the mouth, umbilicus, scrotum and hands are external features of the disease, which may suggest the diagnosis [25] . Proteinuria occurs in the second decade, heralding decline in glomerular filtration rate and progression to end-stage renal disease in a proportion of patients, while concentric LVH and conduction abnormalities emerge subsequently. Along with pain, neurological manifestations include hearing loss, central nervous system white matter lesions of unknown pathogenesis, transient ischaemic attack and stroke [26] . Despite the X-linked inheritance, females may manifest any of the clinical features of Fabry disease, and while often of later onset and milder severity compared with males, significant clinical events including renal failure, arrhythmias and stroke are described. This finding emphasizes the importance of local enzyme activity and substrate accumulation in the tissues compared with other X-linked disorders such as haemophilia, where a small percentage of normal enzyme activity may function effectively within the circulation. The particularly variable severity in females is probably related to the random nature of X-inactivation, with recent studies demonstrating a relationship between clinical features, enzyme activity and X-inactivation in the peripheral blood [27] . Further work is required to confirm the relevance of X-inactivation in cardiac and renal tissues on local organ manifestations.
More recently, case finding studies aimed at patients with single organ manifestations such as renal failure, LVH and stroke have facilitated the diagnosis of patients with apparently later onset manifestations and more preserved enzyme activity (nonclassical disease). Although diagnosis is later due to the absence of childhood suggestive symptoms such as acroparesthesia and angiokeratoma, organ manifestations may be comparable to the classical form, with similar burden of organspecific morbidity.
CARDIAC FEATURES
Features of the cardiac involvement of Fabry disease include LVH, rarely with left ventricular outflow tract obstruction, impaired myocardial function and progressive myocardial fibrosis, resulting in chest pain, heart failure and arrhythmias, including, on occasion, sudden cardiac death [28] . Perinuclear vacuolation, intracytoplasmic whorled bodies, myocyte hypertrophy and fibrosis have been described on cardiac biopsy and at postmortem with macroscopic findings of LVH, posterior wall thinning and mild right ventricular hypertrophy. Coronary arteries are thickened without occlusion of the lumen, with little atherosclerotic disease, and while valvular abnormalities have been described, they are rarely clinically significant [29] .
ECG abnormalities, such as shortened PR interval, LVH on voltage criteria and T wave inversion, are also early findings and may precede detection of LVH on echocardiography. Pacing for atrioventricular and sinus node disease is relatively common; QRS duration and PR interval were found to be independent predictors of future antibradycardia pacing [30] .
Risk factors most strongly associated with cardiovascular events of myocardial infarction (MI), heart failure and death in both sexes were found to be hypertension and LVH [31] . Patients with renal involvement have been found to have more severe cardiac disease. Class 5 chronic kidney disease (CKD5) was associated with worse baseline cardiac parameters and progressive LVH. LVMI increased by 35.4 AE 31.8 g/m 2.7 in CKD5 vs. 5.7 AE 7.9 g/m 2.7 in non-CKD5 (P ¼ 0.044), and cardiovascular events (including sudden death, arrhythmia and pacing device insertion) occurred in 100% of patients with CKD5 (21 events) compared with 26% in non-CKD5 patients (seven events) [32] . However, the type of mutation does not appear to be associated with cardiac outcome. In a study of 207 consecutive patients from one cardiology clinic (47% male, mean age 44 years), 28% had mutations associated with a cardiac predominant phenotype, 10% developed severe heart failure [New York Heart Association (NYHA) ! 3], 6% developed atrial fibrillation, 6% received a device for bradycardia, and 3% cardiac deaths were recorded. When a composite endpoint of new onset atrial fibrillation, NYHA ! 3, device 
MYOCARDIAL FIBROSIS: CARDIAC IMAGING AND BIOMARKERS
Myocardial fibrosis, a common finding within the posterior wall at post mortem, appears to correspond with posterior wall late gadolinium enhancement on cardiac magnetic resonance (CMR) imaging [34] . Patients with high annual increase in left ventricular fibrosis are at risk for sudden cardiac death. In males, fibrosis is generally detected subsequent to emergence of LVH. One study found that late enhancement was not seen with enddiastolic left ventricle (LV) wall thickness less than 12 mm (LV mass <99 g/m 2 ) and was always associated with low systolic strain rate; however, in females, fibrosis was described prior to LVH, and the severity of functional impairment was independent of LV wall thickness [35] . This finding has possible implications for the timing of initiation of specific therapy, since late gadolinium enhancement was associated with increased LV mass, worse myocardial function and failure of regression with ERT [36] . Similarly, abnormalities on 2D speckletracking were independent of LVH in patients with normal ejection fraction; Morris et al. [37] found that principal factors linked to reduced myocardial function include LV septal wall thickness greater than 15 mm, right ventricle (RV) free wall thickness greater than 7 mm and LV longitudinal dysfunction. LV and RV fibrosis were also linked to reduced LV and RV strain, and patients with reduced LV, RV and left atrium (LA) strain had a worse functional class.
A recent sophistication of Fabry CMR imaging is noncontrast T-1 mapping, where lipid is known to reduce the T1 parameter and was hypothesized to detect early cardiac involvement. T1 in Fabry disease appears to be discriminatory of other disorders causing LVH, such as hypertension, hypertrophic cardiomyopathy and amyloid, and also to correlate inversely with LV wall thickness. Low T1 may represent sphingolipid infiltration and 'pseudonormalization' in the posterior wall fibrosis; however, correlative biopsy data is not yet available [38] . Low T1 appears to occur in some patients before hypertrophy and may be a marker of early involvement and a possible imaging marker of treatment effect.
Potential circulating biomarkers include both substrate and related compounds and downstream markers of pathophysiology, including fibrosis. Reports are varied as to the effects of lyso-Gb3 on collagen synthesis [9 && ,39 && ]. However, matrix metalloproteinase 9 was significantly higher in Fabry disease and correlated positively with MSSI and negatively with endocardial fraction shortening [40] . N-terminal of the prohormone brain natriuretic peptide (NT-propBNP) is a marker of diastolic dysfunction and correlated with age, creatinine, left atrial index and abnormal ECG [41] .
FABRY-SPECIFIC THERAPY
Current specific therapy for Fabry disease entails intravenous infusion of recombinant (agalsidase beta; Fabrazyme, Sanofi Genzyme) or gene-activated (agalsidase alfa; Replagal, Shire) preparations of the deficient aGAL. Both preparations have been available for 15 years, and while initial demonstration of effect was based on substrate clearance on biopsy, reduction in pain and left ventricular hypertrophy [3, 4] , longer-term clinical endpoints in patients starting early or later in the course of the disease are now being reported. A recent study of severe clinical events, renal function and cardiac structure in patients from original phase 3 clinical trials who had received agalsidase beta for 10 years found 81% were free of severe clinical events (chronic dialysis, kidney transplant, MI, congestive heart failure, major cardiac procedures, stroke and death) at 10 years, and survival was 94% [42 && ] . Patients classified at the outset as having low or high renal involvement had different slopes in glomerular filtration rate (GFR) (À1.89 vs. À6.82 ml/min/1.73 m 2 /year). Similarly, patients who started treatment later (over 40 years) had increases in interventricular septal thickness (IVST) and left ventricular posterior wall thickness (LPWT) compared with those under the age of 40, who had no change in LPWT, and under 30, who had no change in IVST; patients commencing therapy at !30 years to <40 years had small increases in IVST. Further suggestion of the importance of early therapy is provided in a retrospective registry study of patients receiving agalsidase beta for 5 years, where the risk of severe renal, CV and cerebrovascular clinical events during the first 6 months of therapy was greater in males and patients older than 40 years, and in each case decreased with further time receiving enzyme replacement [43] . In patients with clinical events prior to therapy, the risk of further events during the first 6 months was not different from patients without events, but did increase thereafter.
A single centre retrospective study of patients receiving agalsidase alfa for 10 years found that heart failure classification had improved by at least one class in 22/42 patients, and angina was stable or improved in 41/42 patients. During this time, no patient without LVH at baseline developed LVH. In males with baseline values !50 g/m 2.7 , left ventricular mass index (LVMI) was significantly reduced after 10 years, although in similar females, while an early improvement was noted, mean LVMI was not significantly different from baseline to 10 years [44 && ]. In an attempt to compare long-term registry data of ERT-treated patients with the natural history of untreated patients, data of patients from the Fabry Outcome Survey (a Shire sponsored database) who had received agalsidase alfa for a median of 5 years were compared with published series of untreated patients. A slower decline in renal function and slower progression of LVH were seen in patients receiving agalsidase alfa, and clinical events occurred later in treated patients (16% risk of a composite morbidity event after 24 months with ERT vs. 45% without treatment) [45] .
EMERGING THERAPIES
Recently the utility of active site-specific chaperone therapy that binds and stabilizes mutant protein, facilitating trafficking to the lysosome, has been explored. Results of three phase 2 studies of migalastat HCL (AT-1001, GR181413A, 1-deoxygalactonojirimycin), an orally bioavailable imino sugar, have been presented, indicating increased activity of GLA and reduction of substrate in relevant tissues in vivo [46, 47] . Phase 3 studies are ongoing. The use of substrate reduction therapy by inhibition of glucosyl ceramide synthase is an alternative approach to the development of an oral therapy for Fabry disease that is in early clinical development. Treating Fabry mice with compound Genz-682452 resulted in reduced tissue substrate and a delayed onset of a deficit in thermosensory responses. The effects were most notable in young mice prior to the development of pathology [48] . These products are not yet approved and remain investigational.
CONCLUSION
After 15 years of the availability of ERT for Fabry disease, long-data for the follow up of original trial cohorts and registry studies is demonstrating an effect not only on symptoms and surrogates, including left ventricular mass and GFR, but also on clinical events and mortality. Risk analyses indicate that patients commencing therapy at older ages and later stages of disease are less likely to have a good response to therapy. This new understanding may allow the coherent use of investigations to detect early disease and direct Fabry-specific therapy to the prefibrotic stage of disease, when outcomes might be optimized.
